Europe
The company has suggested that it plans to undercut both Biogen and Novartis on price in order to make up for being third-to-market.
Emma Walmsley, chief executive officer of GlaxoSmithKline, is predicting a good year for her company, with the potential of six regulatory approvals in the United States.
AbbVie reported that its Skyrizi met both primary and all ranked secondary endpoints in its Phase III trial that went head-to-head with Novartis’ Cosentyx in plaque psoriasis.
Helen Tayton-Martin, Adaptimmune’s chief business officer and co-founder, said the partnership with Astellas builds upon and extends an existing collaboration focused on gene editing of iPSC cells.
The deal will increase the availability of next-generation sequencing-based in vitro diagnostic (IVD) tests on Illumina’s diagnostic sequencing systems.
With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area.
MorphoSys AG and Incyte Corporation have inked a collaboration and license deal to further develop and commercialize MorphoSys’ anti-CD19 antibody tafasitamab around the world.
AstraZeneca announced that after a recommendation from an independent Data Monitoring Committee, it was abandoning its Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) for mixed dyslipidemia (MDL).
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
Roivant Sciences, helmed by biotech billionaire Vivek Ramaswamy, launched a new subsidiary, Lokavant, a technology company with the important mission of ensuring that no clinical trial fails due to operational error.
PRESS RELEASES